BRPI0815116A2 - Compostos de triazol que modulam a atividade da hsp90 - Google Patents

Compostos de triazol que modulam a atividade da hsp90

Info

Publication number
BRPI0815116A2
BRPI0815116A2 BRPI0815116-4A2A BRPI0815116A BRPI0815116A2 BR PI0815116 A2 BRPI0815116 A2 BR PI0815116A2 BR PI0815116 A BRPI0815116 A BR PI0815116A BR PI0815116 A2 BRPI0815116 A2 BR PI0815116A2
Authority
BR
Brazil
Prior art keywords
triazole compounds
hsp90 activity
modulate hsp90
modulate
activity
Prior art date
Application number
BRPI0815116-4A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Weiwen Ying
Lijun Sun
Keizo Koya
Dinesh U Chimmanamada
Shijie Zhang
Teresa Przewloka
Hao Li
Original Assignee
Synta Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Pharmaceuticals Corp filed Critical Synta Pharmaceuticals Corp
Publication of BRPI0815116A2 publication Critical patent/BRPI0815116A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0815116-4A2A 2007-08-13 2008-08-13 Compostos de triazol que modulam a atividade da hsp90 BRPI0815116A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96444707P 2007-08-13 2007-08-13
PCT/US2008/009667 WO2009023211A1 (en) 2007-08-13 2008-08-13 Triazole compounds that modulate hsp90 activity

Publications (1)

Publication Number Publication Date
BRPI0815116A2 true BRPI0815116A2 (pt) 2015-01-27

Family

ID=39884398

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815116-4A2A BRPI0815116A2 (pt) 2007-08-13 2008-08-13 Compostos de triazol que modulam a atividade da hsp90

Country Status (14)

Country Link
US (3) US8742133B2 (enExample)
EP (1) EP2193135A1 (enExample)
JP (1) JP5596543B2 (enExample)
KR (1) KR20100057030A (enExample)
CN (1) CN101801983B (enExample)
AU (1) AU2008287367B2 (enExample)
BR (1) BRPI0815116A2 (enExample)
CA (1) CA2695995C (enExample)
IL (1) IL203663A (enExample)
MX (1) MX2010001565A (enExample)
NZ (1) NZ583205A (enExample)
TW (1) TWI438199B (enExample)
WO (1) WO2009023211A1 (enExample)
ZA (1) ZA201001064B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1817295B1 (en) 2004-11-18 2012-11-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2007021966A1 (en) 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
US20070250391A1 (en) * 2006-04-05 2007-10-25 Prade Hendrik D Merchandising system and method for food and non-food items for a meal kit
DK2035396T3 (da) 2006-05-25 2014-06-02 Synta Pharmaceuticals Corp Triazolforbindelser der modulerer hsp90-aktivitet
WO2007139960A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate hsp90 activity and methods for identifying same
WO2007140002A2 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for treating non-hodgkin's lymphoma
US8034834B2 (en) 2006-05-25 2011-10-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders with HSP90 inhibitors
CA2653222A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CN101679319B (zh) 2007-02-08 2014-07-09 辛塔医药品有限公司 用于治疗增生性病症如癌症的三唑类化合物
EP2193135A1 (en) 2007-08-13 2010-06-09 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2009139916A1 (en) * 2008-05-16 2009-11-19 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate hsp90 activity
WO2009148599A1 (en) 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
US8648071B2 (en) 2008-06-27 2014-02-11 Synta Pharmaceuticals Corp. Hydrazonamide compounds that modulate Hsp90 activity
TW201011003A (en) 2008-08-08 2010-03-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
ES2415234T3 (es) * 2008-08-08 2013-07-24 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad Hsp90
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
RS53716B1 (sr) * 2009-10-19 2015-04-30 Synta Pharmaceuticals Corp. Kombinovana terapija kancera sa hsp90 inhibitornim jedinjenjima
EP2560641A2 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
AU2011255438A1 (en) 2010-05-20 2013-01-10 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds
US20130172333A1 (en) 2010-05-20 2013-07-04 Synta Pharmaceuticals Corp. Formulation and dosing of hsp90 inhibitory compounds
EP2575810A1 (en) 2010-05-24 2013-04-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
WO2012026433A1 (ja) 2010-08-23 2012-03-01 第一三共株式会社 三環性ピラゾロピリミジン誘導体のフリー体結晶
US9089570B2 (en) * 2010-09-03 2015-07-28 Tactical Therapeutics Inc Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
AU2011302344B2 (en) 2010-09-13 2015-01-15 Synta Pharmaceuticals Corp. HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
EP2648708A2 (en) 2010-12-08 2013-10-16 Synta Pharmaceuticals Corp. Combination for breast cancer therapy with hsp90 inhibitory compounds
WO2012096919A1 (en) 2011-01-11 2012-07-19 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
EP2678013A1 (en) 2011-02-23 2014-01-01 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with radiotherapy
CN103391779A (zh) 2011-02-24 2013-11-13 辛塔医药品有限公司 使用hsp90抑制性化合物的前列腺癌治疗
US20140045908A1 (en) 2011-02-25 2014-02-13 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
US20140228418A1 (en) * 2011-05-23 2014-08-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
EP2714038A1 (en) 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors
US20140194388A1 (en) * 2011-05-26 2014-07-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with chk inhibitors
EP2729144A2 (en) 2011-07-07 2014-05-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
AU2012332424A1 (en) * 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
CA2853799A1 (en) * 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
US20150119395A1 (en) * 2012-04-04 2015-04-30 Synta Pharmaceuticals Corp. Novel triazole compounds that modulate hsp90 activity
AU2013259267A1 (en) 2012-05-10 2014-11-06 Synta Pharmaceuticals Corp. Treating cancer with Hsp90 inhibitory compounds
CN103664910B (zh) * 2012-09-14 2017-07-04 南京大学 含1,4‑苯并二噁烷的1,2,4‑三氮唑类衍生物及其制法与其抗菌活性
KR101941004B1 (ko) * 2013-03-25 2019-01-23 주식회사 엘지화학 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물
JP6497767B2 (ja) 2013-12-16 2019-04-10 日本化薬株式会社 癌治療におけるhsp90阻害剤の抗腫瘍効果を予測する方法
JP2018504446A (ja) 2015-02-09 2018-02-15 シンタ ファーマシューティカルズ コーポレーション がんを処置するためのhsp90阻害剤およびpd−1阻害剤の組み合わせ治療
EP3300500B9 (en) 2015-05-20 2021-01-13 Amgen Inc. Triazole agonists of the apj receptor
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
EP3541810B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
EP3541802B1 (en) 2016-11-16 2025-01-01 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US11149040B2 (en) 2017-11-03 2021-10-19 Amgen Inc. Fused triazole agonists of the APJ receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
WO2021119358A1 (en) * 2019-12-10 2021-06-17 Washington University Debaryomyces species as an indicator of non-healing ulcers in crohn's disease
CN113121505B (zh) * 2021-03-02 2023-03-07 中国人民解放军海军军医大学 一种具有抗真菌与抗肿瘤双重作用的三唑酮类化合物及应用
WO2022187287A1 (en) * 2021-03-02 2022-09-09 The Johns Hopkins University Anti-fibrotic therapies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU621245B2 (en) * 1989-10-17 1992-03-05 Boehringer Mannheim Gmbh Hydrolase substrates, a process for the preparation thereof and agents containing them
US7329762B2 (en) 2003-06-12 2008-02-12 Merck & Co., Inc. Prodrugs of mitotic kinesin inhibitors
EP1817295B1 (en) * 2004-11-18 2012-11-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102005007304A1 (de) * 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
US8399464B2 (en) 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
CA2598899A1 (en) * 2005-03-09 2006-09-14 Nippon Kayaku Kabushiki Kaisha Novel hsp90 inhibitor
AU2006272652B2 (en) 2005-07-25 2011-06-16 Synta Pharmaceuticals Corp. 1,2,3-triazoles inhibitors of tubulin polymerization for the treatment of proliferative disorders
US20070219129A1 (en) * 2005-08-17 2007-09-20 Pritchard Kirkwood A Jr hsp90 decoy peptides and uses thereof
WO2007021877A1 (en) * 2005-08-18 2007-02-22 Synta Pharmaceuticals Corp. Imidazole compounds that modulate hsp90 activity
CA2618628C (en) 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CA2653222A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DK2035396T3 (da) 2006-05-25 2014-06-02 Synta Pharmaceuticals Corp Triazolforbindelser der modulerer hsp90-aktivitet
WO2007139952A2 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for the preparation of triazole compounds with hsp90 modulating activity
EP2038262B1 (en) 2006-05-25 2014-11-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102007002715A1 (de) * 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
EP2193135A1 (en) * 2007-08-13 2010-06-09 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity

Also Published As

Publication number Publication date
CA2695995C (en) 2015-09-29
MX2010001565A (es) 2010-04-27
US9120745B2 (en) 2015-09-01
NZ583205A (en) 2012-03-30
CN101801983A (zh) 2010-08-11
CA2695995A1 (en) 2009-02-19
US8742133B2 (en) 2014-06-03
JP5596543B2 (ja) 2014-09-24
CN101801983B (zh) 2014-01-29
TW200911788A (en) 2009-03-16
AU2008287367B2 (en) 2012-02-23
US20140296186A1 (en) 2014-10-02
JP2010536753A (ja) 2010-12-02
WO2009023211A1 (en) 2009-02-19
US20150366885A1 (en) 2015-12-24
ZA201001064B (en) 2010-10-27
EP2193135A1 (en) 2010-06-09
TWI438199B (zh) 2014-05-21
US20110195094A1 (en) 2011-08-11
AU2008287367A1 (en) 2009-02-19
KR20100057030A (ko) 2010-05-28
IL203663A (en) 2015-08-31

Similar Documents

Publication Publication Date Title
BRPI0815116A2 (pt) Compostos de triazol que modulam a atividade da hsp90
PT2408787E (pt) Compostos de triazol que modulam a actividade da hsp90
IL200241A0 (en) Triazole compounds that modulate hsp90 activity
SI2035396T1 (sl) Triazolne spojine, ki modulirajo aktivnost HSP90
PL2328893T3 (pl) Związki triazolowe modulujące aktywność Hsp90
IL183108A0 (en) Triazole compounds that modulate hsp90 activity
EP2066948A4 (en) ACCESS COVER FOR PRESSURED BOND DRAWER
IL193159A0 (en) Pyridin-4- ylmethylamides for combating pests
IL194744A0 (en) Trisubstituted 1,2,4-triazoles
EP1988083A4 (en) triazole
BRPI0821357A2 (pt) derivados de oxadiazois de triazol
BRPI0811103A2 (pt) Compostos triazol para tratamento de formação de biopelícula
IL195838A0 (en) Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane compounds
IL205101A0 (en) Trisubstituted 1, 2, 4 - triazoles
GB0807400D0 (en) Modular shoe storage system
HK1144820A (en) Triazole compounds that modulate hsp90 activity
HK1121154A (en) Imidazole compounds that modulate hsp90 activity
HK1119706A (en) Triazole compounds that modulate hsp90 activity
AU2007100472A4 (en) Re-chargeable Pacemaker system
GB0706241D0 (en) Viv suppression system
AU2007901965A0 (en) A partition management system
IL198817A0 (en) Substituted 1-(azolin-2-yl)-amino-1,2-heterocyclyl-ethane compounds for combating pests
AU2006900914A0 (en) Imidazole compounds
SI1817295T1 (sl) Triazolne spojine, ki modulirajo aktivnost hsp90
GB0714052D0 (en) Combatting termite activity

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)